 |
|
|
| |
Exposure-Response Analysis of Islatravir 0.25 mg With Doravirine 100 mg Once Daily in Treatment-Naive and Virologically Suppressed People Living With HIV-1 at Week 48
|
| |
| |
IDSA Oct 21-24 Wash DC
Michelle M. Pham1; Brian Adam2; Ayman Akil2; Bill Poland2; Youwei Bi1; Michelle C. Fox1; Ryan Vargo1; Munjal Patel1,*
1Merck & Co., Inc., Rahway, NJ, USA; 2Certara, Princeton, NJ, USA
|
| |
|
|
|
|
|
